NFSG
ALXN

Newbridge Financial Services Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Newbridge Financial Services Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-101
Closed -$19K – 1678
2021
Q2 		$19K Hold
101
– – 0.01% 802
2021
Q1 		$15K Buy
101
+38
+60% +$5.88K 0.01% 778
2020
Q4 		$10K Hold
63
– – 0.01% 745
2020
Q3 		$7K Buy
+63
New +$6.8K 0.01% 767

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Newbridge Financial Services Group's ALXN Position: Q3 2021 in Review

Newbridge Financial Services Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 101 shares — an estimated $19K sold.

Newbridge Financial Services Group first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $19K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Newbridge Financial Services Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Newbridge Financial Services Group sold 101 Alexion Pharmaceuticals shares in Q3 2021, an estimated $19K.
  • Newbridge Financial Services Group first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Newbridge Financial Services Group's Alexion Pharmaceuticals position peaked at $19K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Newbridge Financial Services Group's 13F filing for Q3 2021, filed 27 Oct 2021.